81 related articles for article (PubMed ID: 9141469)
1. Mechanism of p53 degradation.
Brown JP; Pagano M
Biochim Biophys Acta; 1997 Apr; 1332(2):O1-6. PubMed ID: 9141469
[No Abstract] [Full Text] [Related]
2. Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6.
Crook T; Ludwig RL; Marston NJ; Willkomm D; Vousden KH
Virology; 1996 Mar; 217(1):285-92. PubMed ID: 8599213
[TBL] [Abstract][Full Text] [Related]
3. Immunoexpression of mutant p53 and human papillomavirus related E6 oncoprotein in anal malignancies.
Gupta S; Sharma BK
Indian J Exp Biol; 1998 Sep; 36(9):875-8. PubMed ID: 9854426
[TBL] [Abstract][Full Text] [Related]
4. Interaction of HPV E6 with p53 and associated proteins.
Crook T; Vousden KH
Biochem Soc Trans; 1994 Feb; 22(1):52-5. PubMed ID: 8206279
[No Abstract] [Full Text] [Related]
5. p53 polymorphism and risk of cervical cancer.
Hildesheim A; Schiffman M; Brinton LA; Fraumeni JF; Herrero R; Bratti MC; Schwartz P; Mortel R; Barnes W; Greenberg M; McGowan L; Scott DR; Martin M; Herrera JE; Carrington M
Nature; 1998 Dec; 396(6711):531-2. PubMed ID: 9859989
[No Abstract] [Full Text] [Related]
6. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase.
Kao WH; Beaudenon SL; Talis AL; Huibregtse JM; Howley PM
J Virol; 2000 Jul; 74(14):6408-17. PubMed ID: 10864652
[TBL] [Abstract][Full Text] [Related]
7. p53 polymorphism and risk of cervical cancer.
Josefsson AM; Magnusson PK; Ylitalo N; Quarforth-Tubbin P; Pontén J; Adami HO; Gyllensten UB
Nature; 1998 Dec; 396(6711):531; author reply 532. PubMed ID: 9859988
[No Abstract] [Full Text] [Related]
8. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
Mantovani F; Banks L
Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
[TBL] [Abstract][Full Text] [Related]
9. A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation.
Gu J; Rubin RM; Yuan ZM
Oncogene; 2001 Jun; 20(27):3519-27. PubMed ID: 11429698
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumour suppressor gene proteins in oesophageal cancer.
Agarwal SK; Chatterji A; Bhambhani S; Sharma BK
Indian J Exp Biol; 1998 Jun; 36(6):559-63. PubMed ID: 9731468
[TBL] [Abstract][Full Text] [Related]
11. The role of TP53 in Cervical carcinogenesis.
Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I
Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117
[TBL] [Abstract][Full Text] [Related]
12. Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes.
Vousden K
FASEB J; 1993 Jul; 7(10):872-9. PubMed ID: 8393818
[TBL] [Abstract][Full Text] [Related]
13. Application of homogeneous time-resolved fluorescence (HTRFTM) to monitor poly-ubiquitination of wild-type p53.
Yabuki N; Watanabe S; Kudoh T; Nihira Si; Miyamato C
Comb Chem High Throughput Screen; 1999 Oct; 2(5):279-87. PubMed ID: 10539989
[TBL] [Abstract][Full Text] [Related]
14. p53-Dependent and -independent transactivation by the E6 protein of human papillomavirus type 16.
Akutsu N; Shirasawa H; Asano T; Isono K; Simizu B
J Gen Virol; 1996 Mar; 77 ( Pt 3)():459-63. PubMed ID: 8601782
[TBL] [Abstract][Full Text] [Related]
15. p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6.
Molinari M; Milner J
Oncogene; 1995 May; 10(9):1849-54. PubMed ID: 7753560
[TBL] [Abstract][Full Text] [Related]
16. Biological activities of p53 mutants in Burkitt's lymphoma cells.
Vousden KH; Crook T; Farrell PJ
J Gen Virol; 1993 May; 74 ( Pt 5)():803-10. PubMed ID: 8492087
[TBL] [Abstract][Full Text] [Related]
17. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
Mansur CP; Marcus B; Dalal S; Androphy EJ
Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
[TBL] [Abstract][Full Text] [Related]
18. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.
Storey A; Thomas M; Kalita A; Harwood C; Gardiol D; Mantovani F; Breuer J; Leigh IM; Matlashewski G; Banks L
Nature; 1998 May; 393(6682):229-34. PubMed ID: 9607760
[TBL] [Abstract][Full Text] [Related]
19. HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes.
Kawamata Y; Mitsuhashi A; Unno Y; Kado S; Shino Y; Uesugi K; Eguchi O; Ishii J; Seki K; Sekiya S; Shirasawa H
Int J Oncol; 2002 Sep; 21(3):561-7. PubMed ID: 12168100
[TBL] [Abstract][Full Text] [Related]
20. Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation.
Medcalf EA; Milner J
Oncogene; 1993 Oct; 8(10):2847-51. PubMed ID: 7690928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
